A Phase IV, Open-Label Administration (The Trial Statistician and Laboratory Technicians will be Blinded to Group Assignment), Randomized (Group 1 and 2), Parallel-Group, Multicenter Trial to Evaluate the Immunogenicity and Safety of 2 Doses of